Halozyme Therapeutics Inc. buy Benchmark Co.
Start price
19.01.24
/
50%
€31.35
Target price
19.01.25
€45.94
Performance (%)
29.19%
Price
14.05.24
€40.50
Summary
This prediction is currently active. The BUY prediction by Benchmark_Co_ currently has a performance of 29.19%. This prediction currently runs until 19.01.25. The prediction end date can be changed by Benchmark_Co_ at any time. Benchmark_Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Halozyme Therapeutics Inc. | 5.634% | 5.634% |
iShares Core DAX® | 1.662% | 4.835% |
iShares Nasdaq 100 | 0.667% | 0.000% |
iShares Nikkei 225® | -2.139% | -4.786% |
iShares S&P 500 | 0.564% | 0.775% |
Comments by Benchmark_Co_ for this prediction
In the thread Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Stopped prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€36.23
16.04.24
16.04.24
€46.98
16.04.25
16.04.25
11.87%
14.05.24
14.05.24
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€33.23
20.10.23
20.10.23
€47.17
20.10.24
20.10.24
21.88%
14.05.24
14.05.24